Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 7/3067% above fair value

$3.45−0.07 (-1.99%)

Close on Nov 13, 2026Market cap $275.32MP/E –Yield –

Prelude Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Prelude Therapeutics's price to sales ratio was 14.2× on Nov 11, 2026, against 12.2× a year earlier.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	14.2×	−6.8
2025	Dec 31, 2025	21.0×	–

Parsed from the XBRL in Prelude Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRLD.

Revenue growth220.3% · median 16.4%

Operating margin-300.6% · median -907.9%

Net margin-269.7% · median -578.2%

Advertisement
300 × 250

See a number that looks wrong?